Our Vision
PMD Solutions was founded by Myles Murray to void the fundamental clinical need to measure patients breathing rates, which if amiss, is a significant indicator of an adverse event. The creation of RespiraSense has revolutionised the early diagnosis and intervention of medical events, making every breath count.
OUR SOLUTIONS IMPROVE PATIENT CARE AND MEDICAL OUTCOMES ACROSS THE GLOBE.
PMD Core Values
Our core values of Leadership, Continuous Improvement, Integrity and High Standards are an active component of everything PMD and its team does every day to interact with our stakeholders. These are our Values and we all aim to live by these every day.
PMD Solutions as a company aims to lead the way in terms of innovative products having patients motivating everything we do. To achieve this we collectively and individually demonstrate leadership in how we do our jobs, how we interact and communicate with each other and our stakeholders.
At PMD Solutions we have and seek to have the highest standards in everything we do. By achieving this we will always deliver the best results we possibly can. PMD Solutions collectively and individually strive to improve on what we did yesterday. We define and measure excellence and success in quality of patient care and our products. We build the skills in our people to continuously strive to be better and to help save lives.
PMD Solutions individually and collectively will follow moral and ethical thought processes to always achieve the appropriate outcome in all circumstances. We strive to achieve this in all interactions and relationships with colleague, customers, and stakeholders.
Our History
ISO 27001-2017 certification achieved
PMD chosen to be part of the DigitalHealthLondon. accelerator programme
PMD proud to be part of the IGNITE 2023 Cohort (Mass Medical)
NICE Early Evaluation Assessment indicates PMD for virtual Wards in UK
Myles Murray CEO names by Cork Business Association as Cork Entrepreneur of the year 2023
Letterkenny Community Virtual Ward goes live
Rollout to all acute hospitals in Ireland completed
Patents granted EU & US
NICE MIB (Medtech Innovation Brief) Published
Pilot in Letterkenny for a hospital at home project with successful outcomes
FDA approval achieved.
Cyber Essentials and Cyber Essentials Plus certification achieved
NHSx fund Nottingham University Hospital evaluation of RespiraSense, NHS, UK – Pilot ongoing
As a result of the successful demonstrator site in CUH the HSE awarded PMD a national rollout to all Respiratory wards in the acute hospitals across the country.
Papers published;
McCartan Paper - predictions of hypoxia
Javanbakht Paper - health economics
PMD were the Overall winner of the Irish Times Innovation Award 2021 and also the winner of the Life Science and healthcare section
PMD were shortlisted for the Irish Healthcare Awards 2021
Medtech – awarded PMD solutions as the Top Respiratory Device providers 2021
GHP Healthcare and Pharmaceutical Awards 2021- Best Respiratory Compromise Monitoring Solution 2021 - RespiraSense
RespiraSense used with COVID-19 patients to monitor their respiratory behaviours without the need of manually measuring the breathing of patients.
PMD’s RespiraSense trials produce a successful outcome in Dublin Hospital efficacy study on the predictability of events using electronic continuous respiratory rate monitoring.
RespiraSense in use in Cork University Hospital as demonstrator site for National Rollout.
PMD Solutions awarded European Space Agency contract to fight COVID-19.
RespiraSense presented two clinical posters at the British Obesity and Metabolic Surgery Society.
PMD awarded a position onto the London Stock Exchange’s Elite programme.
Distribution agreements for the Kingdom of Saudi Arabia and Canada agreed.
PMD’s patent approved for the Japanese market.
RespiraSense Version 3 is finalized and commercialised.
PMD achieves positive outcome from phase two (b) clinical validation of its population Sleep Apnoea screening solution in Mallow General Hospital Ireland.
PMD accepted onto the Irish Stock Exchange’s #IPOReady programme.
PMD’s patent approved for the Chinese market.
Frost & Sullivan Awards PMD Solutions with Visionary Innovation Leadership Award in London.
UCL Partners is supporting four trusts to pilot RespiraSense across 4 NHS hospitals.
Awarded SBRI Healthcare funding for improving patient flow in acute care in the NHS.
PMD becomes Gold Sponsor for the 13th International Conference on Rapid Response Systems and Medical Emergency Teams in Chicago.
PMD achieves positive outcome from phase two (a) clinical validation of its population Sleep Apnoea screening solution in Mallow General Hospital Ireland.
PMD Solutions selected as innovative respiratory device leader to join the NHS Innovation Accelerator Programme.
Myles Murray CEO made a fellow of the NHS Innovation Accelerator (NIA).
PMD wins dotMED 2016 Health Technology award.
PMD attends 12th International Conference on Rapid Response Systems and Medical Emergency Teams in Melbourne.
PMD Solutions reaches the finals for Best Emerging Company in the Irish Medical Device Association Excellence Awards.
PMD achieves positive outcome from its phase one clinical validation of its population Sleep Apnoea screening solution in Mallow General Hospital Ireland.
Funding Injection- PMD secures €4.265 million in funding from Horizon 2020 SME Instrument.
RespiraSense gets CE Mark approval for first generation RespiraSense.
Awarded Enterprise Ireland High Potential Start-Up status.
Start-Up Academy of Excellence Winner.
IMDA Medical Technology Industry Excellence Emerging Company of the Year.
PMD awarded a place on the new NDRC’s VentureLab program.
Winner of Highly Commended Award from Intertrade Ireland All-Island Seedcom Competition.
PMD raises €450,000 through Enterprise Ireland, Industrial, and Angel Investment.
Finalist of the Genesis Enterprise Emerging Business of the Year award.
Awarded Best of Class at Cork Entrepreneurial Experience.
Invention wins Cork Institute of Technology’s Prize for Innovation: first place.
PMD Solutions is founded and begins developing its first prototype.
Selected for the Genesis Enterprise Program.
Clinical need highlighted and development begins.
